In the multicenter study by Prattes et al. [4], CAPA diagnosis was associated with older age, with any form of invasive support, and with treatment with anti-IL-6 (tocilizumab) (HR: 2.45; 95% CI 1.41–4.25). This evidence concerns the gene IL6 and episodic ataxia type 2.